Evidence map›Paper›PMID 38740955›Full record

ArticleNature materials2024

Accelerating ionizable lipid discovery for mRNA delivery using machine learning and combinatorial chemistry.

Bowen Li, Idris O Raji, Akiva G R Gordon, Lizhuang Sun, Theresa M Raimondo, Favour A Oladimeji, Allen Y Jiang, Andrew Varley, Robert S Langer, Daniel G Anderson

Abstract read
PubMed Publisher
In one paragraph

Article in Nature materials, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 111 papers.

0numbers the graph read from it
0cells of the map it votes in
111citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

111 citing papers in PubMed.

  1. Review
  2. Cas12a chRDNA-mediatedMolecular therapy. Nucleic acids · 2026
    Article
  3. Review
  4. Article
  5. Review
  6. New approach methodologies (NAMs) for preclinical and translational evaluation of mRNA-lipid nanoparticle (LNP) therapeutics.Journal of controlled release : official journal of the Controlled Release Society · 2026
    Review
  7. Codon-optimizedMolecular therapy. Nucleic acids · 2026
    Article
  8. Review
  9. Review
  10. Article
  11. Review
  12. Review
  13. Review
  14. Review
  15. Review
  16. Article
  17. Review
  18. Review
  19. Review
  20. AI meets high-throughput screening of LNPs.Nature biomedical engineering · 2026
    Article

51 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Bowen Li *David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, USA. bw.li@utoronto.ca.ORCID 0000-0001-5006-9143
Idris O Raji *David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, USA.ORCID 0000-0001-5697-6422
Akiva G R Gordon *David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, USA.ORCID 0000-0002-6679-2974
Lizhuang SunDepartment of Statistics, University of Michigan, Ann Arbor, MI, USA.
Theresa M RaimondoDavid H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, USA.ORCID 0000-0001-8261-8602
Favour A OladimejiHarvard and MIT Division of Health Science and Technology, Massachusetts Institute of Technology, Cambridge, MA, USA.
Allen Y JiangDavid H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, USA.ORCID 0000-0002-9826-5976
Andrew VarleyLeslie Dan Faculty of Pharmacy, University of Toronto, Toronto, Ontario, Canada.ORCID 0000-0002-1518-2703
Robert S LangerDavid H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, USA.ORCID 0000-0003-4255-0492
Daniel G AndersonDavid H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, USA. dgander@mit.edu.ORCID 0000-0001-5629-4798

Funding

Combinatorial and computational design of bnAb mRNA vaccines for HIVR61AI161805 · NIAID · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI ANDERSON, DANIEL G · 2021 to 2023
$2.1M
NIAID NIH HHS R61 AI161805
6 · The paper itself

Abstract

To unlock the full promise of messenger (mRNA) therapies, expanding the toolkit of lipid nanoparticles is paramount. However, a pivotal component of lipid nanoparticle development that remains a bottleneck is identifying new ionizable lipids. Here we describe an accelerated approach to discovering effective ionizable lipids for mRNA delivery that combines machine learning with advanced combinatorial chemistry tools. Starting from a simple four-component reaction platform, we create a chemically diverse library of 584 ionizable lipids. We screen the mRNA transfection potencies of lipid nanoparticles containing those lipids and use the data as a foundational dataset for training various machine learning models. We choose the best-performing model to probe an expansive virtual library of 40,000 lipids, synthesizing and experimentally evaluating the top 16 lipids flagged. We identify lipid 119-23, which outperforms established benchmark lipids in transfecting muscle and immune cells in several tissues. This approach facilitates the creation and evaluation of versatile ionizable lipid libraries, advancing the formulation of lipid nanoparticles for precise mRNA delivery.

Indexed as

Combinatorial Chemistry TechniquesLipidsMachine LearningRNA, MessengerAnimalsHumansMiceNanoparticlesLipidsRNA, Messenger

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.